April 16, 2023 11:00 AM EDTUpdated April 17, 04:06 PM
R&D
Pharma

Mod­er­na and Mer­ck pre­pare for PhI­II tri­al of can­cer vac­cine, and an ex­pan­sion to lung can­cer: #AACR23

Nicole DeFeudis

Editor

OR­LAN­DO – Mod­er­na and Mer­ck plan to launch a Phase III study this year for their per­son­al­ized can­cer vac­cine in melanoma, and have re­vealed more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

A service from the Financial Times